Prospective Determination of the Incidence and Risk Factors of New‐Onset Uveitis in Juvenile Idiopathic Arthritis: The Research in Arthritis in Canadian Children Emphasizing Outcomes Cohort. Issue 11 (29th October 2019)

• Record Type: Journal Article
• Authors: Lee, Jennifer J. Y.; Duffy, Ciarán M.; Guzman, Jaime; Oen, Kiem; Barrowman, Nick; Rosenberg, Alan M.; Shiff, Natalie J.; Boire, Gilles; Stringer, Elizabeth; Spiegel, Lynn; Morishita, Kimberly A.; Lang, Bianca; Reddy, Deepti; Huber, Adam M.; Cabral, David A.; Feldman, Brian M.; Yeung, Rae S. M.; Tucker, Lori B.; Watanabe Duffy, Karen
• Is Part Of: Arthritis care & research. Volume 71:Issue 11(2019)
• Page Start: 1436
• Page End: 1443
• Publication Date: 2019-10-29
• Subjects: Arthritis -- Periodicals; Rheumatism -- Periodicals; 616.72
• DOI: 10.1002/acr.23783
• Languages: English
• ISSNs: 2151-464X

Abstract

Abstract : Objective: Identification of the incidence of juvenile idiopathic arthritis (JIA)–associated uveitis and its risk factors is essential to optimize early detection. Data from the Research in Arthritis in Canadian Children Emphasizing Outcomes inception cohort were used to estimate the annual incidence of new‐onset uveitis following JIA diagnosis and to identify associated risk factors. Methods: Data were reported every 6 months for 2 years, then yearly to 5 years. Incidence was determined by Kaplan‐Meier estimators with time of JIA diagnosis as the reference point. Univariate log‐rank analysis identified risk factors and Cox regression determined independent predictors. Results: In total, 1, 183 patients who enrolled within 6 months of JIA diagnosis met inclusion criteria, median age at diagnosis of 9.0 years (interquartile range [IQR] 3.8–12.9), median follow‐up of 35.2 months (IQR 22.7–48.3). Of these patients, 87 developed uveitis after enrollment. The incidence of new‐onset uveitis was 2.8% per year (95% confidence interval [95% CI] 2.0–3.5) in the first 5 years. The annual incidence decreased during follow‐up but remained at 2.1% (95% CI 0–4.5) in the fifth year, although confidence intervals overlapped. Uveitis was associated with young age (<7 years) at JIA diagnosis (hazard ratio [HR] 8.29, P < 0.001), positive antinuclear antibody (ANA) test (HR 3.20, P < 0.001), oligoarthritis (HR 2.45, P = 0.002), polyarthritis rheumatoid factor negative (HR 1.65, P = 0.002), and female sex (HR 1.80, P = 0.02). In multivariable analysis, only young age at JIA diagnosis and ANA positivity were independent predictors of uveitis. Conclusion: Vigilant uveitis screening should continue for at least 5 years after JIA diagnosis, and priority for screening should be placed on young age (<7 years) at JIA diagnosis and a positive ANA test.